Rheumatoid Arthritis – Emerging Therapies – Olumiant (Baricitinib) Launch Tracking Wave 1

MARKET OUTLOOK

Eli Lilly’s Olumiant is the second-in-class Jak inhibitor approved for rheumatoid arthritis (RA) in the United States. Its launch comes years after the launch of Pfizer’s Jak inhibitor, Xeljanz (approved for RA in 2012). With several other Jak inhibitors in late-phase development for RA (e.g., filgotinib [Galapagos/Gilead], upadacitinib [AbbVie]), physicians’ perceptions of Olumiant and the product’s market performance thus far will offer important insight to Eli Lilly and other companies hoping to penetrate this increasingly crowded space. The Rheumatoid Arthritis Emerging Therapy series includes three waves that will track the awareness, trial, and uptake of Olumiant since its U.S. launch in June 2018 for the treatment of RA. In addition, the series will examine anticipated future trends in RA treatment, particularly Olumiant’s uptake, and assess Lilly’s promotional efforts.

QUESTIONS ANSWERED

  • What is the awareness of, familiarity with, and perceptions related to Olumiant among U.S. rheumatologists?
  • According to surveyed prescribers, to which patients are they prescribing Olumiant, what are the reasons for prescribing the drug, and how satisfied are they with Olumiant?
  • How do prescribers and nonprescribers compare across key metrics?
  • How are the trial and adoption of Olumiant tracking compared with other recent product launches in the autoimmune market?

PRODUCT DESCRIPTION

Emerging Therapies: is a three-wave series based on primary research data collected at one, six, and twelve months post-commercial launch with U.S. physicians. The research captures physicians’ awareness, perceptions, and usage of the launched product, as well as the impact on current therapies and anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.

GEOGRAPHY

United States

PRIMARY RESEARCH

Survey of 75 U.S. rheumatologists for each wave.

KEY METRICS INCLUDED

  • Unaided and Aided Awareness of Olumiant
  • Familiarity with and Impressions of Olumiant
  • Prescriber and Nonprescriber Profiles
  • Willingness to Prescribe Olumiant
  • Performance of Olumiant on Key Attributes
  • Sales Representative Frequency, Reach, and Satisfaction
  • Benchmarking Against Previously Launched Rheumatoid Arthritis Agents

Table of contents

  • Rheumatoid Arthritis - Emerging Therapies - Olumiant (Baricitinib) Launch Tracking Wave 1
    • Rheumatoid Arthritisu2013Emerging Therapiesu2013Olumiantu2013Wave 1 (September 2018)